Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ANL · Why this verdict
Why Adlai Nortye (ANL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Adlai Nortye combines explosive revenue growth with severe cash burn, an unreliable analyst price target, and a business-quality score below the investment floor, leaving the growth narrative overshadowed by financial and data-quality concerns.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Adlai Nortye is showing explosive revenue growth of 178% year-over-year, driving the model's growth score to a maximum 10.0 out of 10 and ranking it as an industry growth leader among peers. Growth breakdown | Revenue growth should stay above 50% YoY over the next 12 months for the growth-leader thesis to hold. | — |
| Counter178% growth off a small base is common in early-stage biotech and doesn't by itself signal a durable, repeatable growth trajectory. | ||
The company is burning cash aggressively, with free cash flow running at -754% of revenue and a Rule of 40 score of -576, both deeply negative and well below sustainability thresholds. Quality breakdown | FCF as a percent of revenue should improve toward breakeven (0%) over the next 12 months to avoid a capital raise. | — |
| CounterHeavy cash burn is normal and even expected for a clinical-stage biotech investing in trials, and doesn't necessarily indicate operational distress. | ||
The model rejected the raw analyst price target of $28.60 as implausible (3.0x the $9.49 spot price) and fell back to a technical take-profit, meaning the bullish analyst-target case for ANL cannot currently be trusted. Bear case | A revised, more plausible analyst target within roughly 1.5x of spot price should emerge over the next 12 months if coverage improves. | — |
| CounterA legitimately large price target isn't automatically wrong for a binary biotech story with a real catalyst, and the rejection may be discarding a valid bullish signal. | ||
Recent trading shows a volume surge of 3.1x average during a selloff alongside falling on-balance volume, indicating distribution pressure even though the stock remains above its 200-day moving average. Momentum breakdown | On-balance volume should turn back to accumulation (rising) within the next 12 months if the selloff pressure is temporary. | — |
| CounterElevated volume on a single selloff day can be a one-off liquidity event (e.g., trial data, financing) rather than a sustained distribution trend. | ||
Adlai Nortye's overall business quality score of 3.3 sits below the model's 4.0 minimum investment floor, triggering an exit recommendation despite the growth story. Key risks | Quality score should rise above 4.0 for the position to clear the model's minimum floor again. | — |
| CounterQuality scoring built around margins and profitability penalizes pre-revenue/pre-profit biotechs structurally, even ones with genuine pipeline value. | ||
Adlai Nortye is showing explosive revenue growth of 178% year-over-year, driving the model's growth score to a maximum 10.0 out of 10 and ranking it as an industry growth leader among peers.
—Growth breakdown
- Expectation
- Revenue growth should stay above 50% YoY over the next 12 months for the growth-leader thesis to hold.
Counter178% growth off a small base is common in early-stage biotech and doesn't by itself signal a durable, repeatable growth trajectory.
The company is burning cash aggressively, with free cash flow running at -754% of revenue and a Rule of 40 score of -576, both deeply negative and well below sustainability thresholds.
—Quality breakdown
- Expectation
- FCF as a percent of revenue should improve toward breakeven (0%) over the next 12 months to avoid a capital raise.
CounterHeavy cash burn is normal and even expected for a clinical-stage biotech investing in trials, and doesn't necessarily indicate operational distress.
The model rejected the raw analyst price target of $28.60 as implausible (3.0x the $9.49 spot price) and fell back to a technical take-profit, meaning the bullish analyst-target case for ANL cannot currently be trusted.
—Bear case
- Expectation
- A revised, more plausible analyst target within roughly 1.5x of spot price should emerge over the next 12 months if coverage improves.
CounterA legitimately large price target isn't automatically wrong for a binary biotech story with a real catalyst, and the rejection may be discarding a valid bullish signal.
Recent trading shows a volume surge of 3.1x average during a selloff alongside falling on-balance volume, indicating distribution pressure even though the stock remains above its 200-day moving average.
—Momentum breakdown
- Expectation
- On-balance volume should turn back to accumulation (rising) within the next 12 months if the selloff pressure is temporary.
CounterElevated volume on a single selloff day can be a one-off liquidity event (e.g., trial data, financing) rather than a sustained distribution trend.
Adlai Nortye's overall business quality score of 3.3 sits below the model's 4.0 minimum investment floor, triggering an exit recommendation despite the growth story.
—Key risks
- Expectation
- Quality score should rise above 4.0 for the position to clear the model's minimum floor again.
CounterQuality scoring built around margins and profitability penalizes pre-revenue/pre-profit biotechs structurally, even ones with genuine pipeline value.
Per-dimension breakdown
Quality
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 2.6 |
| FCF quality | 0.0 |
| Moat | 6.2 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -754% of revenue
- ▸Rule of 40: -576 (fail)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 178% YoY
Momentum
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.8 |
| OBV | 1.0 |
| MA position | 7.0 |
| Volume | 1.3 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 4.8 |
- ▸Analyst upside: 169%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Negligible insider selling — $132 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 9.3 |
- ▸Industry growth leader
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.9 |
| support resistance | 4.0 |
| 52w position | 2.3 |
Risk (lower is worse)
3.4/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 7.1 |
| days to cover | 0.0 |
| volatility | 0.0 |
| beta | 6.6 |
Catalyst
5.0/10data confidence 25%| Component | Sub-score |
|---|---|
| erm | 5.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- ASYMMETRY:8.9>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.7<4.5
Warning (0)
none
Reward-to-Risk
8.94
Upside
+134.1%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 48 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.6B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.7<4.5 outcome against Growth at 10.0 and asymmetric R:R of 8.94.
The strongest dimensions are Growth at 10.0, Value at 9.0, and Insider at 7.3; the weakest are Quality at 3.3, Risk (lower is worse) at 3.4, and Technical at 3.4. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 8.94 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Explosive Revenue Growth
Trip ifRevenue growth falls below 50% YoY for 2 consecutive quarters.
- P2Severe Cash Burn
Trip ifFree cash flow as a percent of revenue rises above -100% for 2 consecutive quarters.
- P3Unreliable Analyst Target Data
Trip ifA new analyst price target falls below 1.5x the spot price, ending the data-quality rejection.
- P4High Momentum Selloff Volume
Trip ifOn-balance volume trend flips to accumulation for more than 2 consecutive months, reversing the current distribution trend.
- P5Quality Below Investment Floor
Trip ifQuality score rises above 4.0 from the current 3.3.